APP Pharma is a pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. APP
Merck Serono’s proprietary oral formulation of cladribine (Cladribine tablets) is a small molecule that may interfere with the behavior and the proliferation of certain white blood cells, particularly
In conjunction with this investment, OptiNose will reincorporate in the US and move its headquarters from Oslo, Norway to Yardley, PA. OptiNose, founded by Per Djupesland in 2000,
Rosetta Genomics said that the ongoing study is designed to examine the ability of miRview mets to identify the primary origin of metastases in patients with cancer of
Lixisenatide is a Zealand-invented GLP-1 (glucagon-like-peptide-1) receptor agonist for the treatment of type-2 Diabetes, and uses Zealand’s proprietary SIP (structure inducing probe) peptide modification technology. Previously, in April
DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects. Depomed claimed that the
Atorvastatin, a cholesterol-reducing medicine is a generic equivalent of the Pfizer’s brand Lipitor, a member of the drug class known as statins. It stabilises plaque and prevents strokes
Cubist Pharma had filed a patent infringement lawsuit against Teva Parenteral Medicines (TPM), Teva Pharmaceuticals USA and Teva Pharmaceutical Industries on March 23, 2009. The complaint alleged infringement
Amy Hu, president and CEO of Niusule, said: “We believe that the animal health products industry in China is promising and will grow rapidly in the next 10
By regulation, the FDA has 60 days to conduct a filing review to determine if the application is sufficiently complete to permit a substantive review. Salix has requested
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.